Sydney, Australia - 01 October 2018 – Imugene Limited (ASX:IMU), a clinical stage immuno- oncology company today announced the appointment of Professor Pravin Kaumaya of Ohio State University Comprehensive Cancer Centre to its Scientific Advisory Board (SAB).
Imugene Managing Director and CEO Leslie Chong said, “Professor Kaumaya is an acknowledged leader in cancer vaccine research and will greatly enhance the insights Imugene receives from its scientific advisory board as we advance our expanded cancer immuno-therapy product pipeline.”
For further information please download PDF attached:
Download this document
